CTIC tanked more than 50% this Monday on the news that FDA panel disapprove their drug pixantrone. Add to that, the biotech investment banker Rodman downgrade its stock on the same day.
Since then, the stock bounced back for two days, from 42 cents to as high as 77 cents, a 71% comeback.
Is CTIC a dead [...]
CYPB
CYPB has tons of cash on hand. Its cash per share value is $3.81. Yet the pile of cash failed to attract investors. Stock price is merely hovering around $5.
Product: Savella – for fibromyalgia
Avise – for theumatoid arthritis
Distribution: By FRX
Next on FDA Calendar:
Sales: 20.68M
Cash on-hand: 144.81M (cash/share = $3.81)
Float: 38M
TA:
Stock is still trending below MA50 $5.33. [...]
Continue reading about Cypress Bioscience, Inc. (CYPB) – cash rich and performance poor?
The shares of world largest drug maker are up almost 2% on Monday following the passage of the healthcare bill.
Here’s the list of pros on the passing of the new legislation:
The market uncertainty was removed with the passing of the legislation, which gives the confidence back to the investors.
The new bill will extend medical benefits [...]
Continue reading about Will Pfizer (PFE) benefit from new Healthcare reform bill?
The US history is in its making. The US House of Representatives passed a historical healthcare bill in a 219-212 vote. All 178 Republicans opposed, along with 34 Democrats. President Obama has won a huge victory with his healthcare reform.
So what’s in it for the shareholders of US healthcare stocks?
The 10-year, $938 billion bill would [...]
Recent Comments